Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Characterize Tumor Hypoxia by Magnetic Resonance Imaging

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03987568
Recruitment Status : Recruiting
First Posted : June 17, 2019
Last Update Posted : July 12, 2019
Sponsor:
Information provided by (Responsible Party):
Wake Forest University Health Sciences

Brief Summary:
The purpose of this research study is to measure the hypoxia (low oxygen condition) in prostate cancers and its effect in survival. In this study, investigators will assess hypoxia by magnetic resonance imaging (MRI) and create a hypoxia score. Investigators will study the hypoxia score and how it correlates (if any) to the disease aggressiveness as well as its effect on the treatment outcomes.

Condition or disease Intervention/treatment
Prostate Cancer Prostate Tumor Other: Blood draws Diagnostic Test: Magnetic resonance imaging (MRI)

Detailed Description:

Primary Objective(s):

  • To assess hypoxia in primary prostate tumors by magnetic resonance imaging.
  • To correlate hypoxic score with disease aggressiveness (proliferation biomarkers' expression).

Secondary Objective(s):

  • To correlate hypoxic score with ExoHypoxic concentration in plasma of same patient.
  • To correlate hypoxic score with fatty acid synthase (FASN) expression.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 40 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: To Characterize Tumor Hypoxia by Magnetic Resonance Imaging in African American and Caucasian Prostate Cancer Patients
Estimated Study Start Date : July 10, 2019
Estimated Primary Completion Date : September 2021
Estimated Study Completion Date : October 2021

Resource links provided by the National Library of Medicine



Intervention Details:
  • Other: Blood draws
    Blood draws at two specified timepoints - the first is during the MRI and the second is scheduled during participant's prostatectomy.
  • Diagnostic Test: Magnetic resonance imaging (MRI)
    At the beginning of study magnetic resonance imaging MRI will be completed.


Primary Outcome Measures :
  1. Differences in Tumor Hypoxia Scores Between Subgroups [ Time Frame: 30 days ]
    Using MRI parameters including apparent diffusion coefficient and fractional blood value four race/score combination groups (African-Americans with Gleason score 6; African-Americans with Gleason score greater than or equal to 7; Caucasians with Gleason score 6; and Caucasian with Gleason score greater than or equal to 7) to calculate the correlation coefficients estimates between hypoxic scores using Pearson correlation coefficient and Spearman's rank correlation coefficient.

  2. Number of Biomarkers Expressed [ Time Frame: 30 days ]
    Expression of proliferation biomarkers (Ki-67 and PCNA) to calculate the correlation coefficients estimates between expression of proliferation biomarkers using Pearson correlation coefficient and Spearman's rank correlation coefficient.


Secondary Outcome Measures :
  1. ExoHypoxic Concentrations in Plasma [ Time Frame: 30 days ]
    The associations between hypoxic score and candidate biomarkers for ExoHypoxic concentration (number per milliliter plasma) will be estimated using partial Spearman's rank correlation coefficient where the race/score combination groups are adjusted.

  2. Number of Fatty Acid Synthase Expressions in Prostate Cancer and ExoHypoxic Concentrations [ Time Frame: 30 days ]
    The associations between hypoxic score and fatty acid synthase expression will be estimated using partial Spearman's rank correlation coefficient where the race/score combination groups are adjusted.


Biospecimen Retention:   Samples With DNA
Blood draws


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Caucasian and African-American males with prostate cancer having not yet undergone therapy (drugs, radiation or prostatectomy) planning to undergo a radical prostatectomy as standard of care.
Criteria

Inclusion Criteria:

  • The minimum age for this study is men 40 years and older. Prostate cancer mainly affects men over the age of 40.
  • Patients with Caucasian and African American race
  • Patients with pathology-proven prostate cancer (Gleason 6 or higher)
  • Patients who have not yet undergone therapy (systemic drugs, radiation, or prostatectomy)
  • Patients who will have a radical prostatectomy as standard of care.
  • Ability to understand and the willingness to sign an IRB-approved informed consent document (either directly or via a legally authorized representative).

Exclusion Criteria:

  • Patients who have already received some form of treatment or are not planning to undergo radical prostatectomy for treatment.
  • Patients with any other cancer along with prostate cancer.
  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03987568


Contacts
Layout table for location contacts
Contact: Jennifer Thomas, RN 336-716-5440 jethomas@wakehealth.edu

Locations
Layout table for location information
United States, North Carolina
Wake Forest Baptist Comprehensive Cancer Center Recruiting
Winston-Salem, North Carolina, United States, 27157
Contact: Jennifer Thomas, RN         
Sponsors and Collaborators
Wake Forest University Health Sciences
Investigators
Layout table for investigator information
Principal Investigator: Gagan Dee[, Ph.D Wake Forest University Health Sciences

Layout table for additonal information
Responsible Party: Wake Forest University Health Sciences
ClinicalTrials.gov Identifier: NCT03987568     History of Changes
Other Study ID Numbers: IRB00059037
WFBCCC 03319 ( Other Identifier: Wake Forest Baptist Comprenhensive Cancer Center )
First Posted: June 17, 2019    Key Record Dates
Last Update Posted: July 12, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Hypoxia
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms